LN-4311 / LigaChem Biosci, Nectin Therap - LARVOL DELTA

LN-4305 and LN-4311 novel Nectin-4 targeting ADCs with best-in-class-potential (ESMO 2025) - "The landmark approval of Enfortumab-Vedotin (EV), the first Nectin-4 directed ADC, in advanced urothelial carcinoma, set a strong proof-of-concept for this approach and spurred a wave of next-generation ADCs, aiming at overcoming safety challenges and expanding into other cancer indications. Legal entity responsible for the study The authors. Funding Nectin Therapeutics, Ligachem Biosciences."

Oncology • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • NECTIN4

The other poster introduced LN4305 (topoisomerase I payload) and LN4311 (MMAE payload), both Nectin-4-targeting ADC candidates that LCB is co-developing with Nectin Therapeutics. (The Bio) - "LN4305 and LN4311 demonstrated durable tumor reduction and, in some cases, complete remission (CR) following a single administration in a refractory relapse model previously treated with Padcev. Sustained tumor suppression was also observed in models of triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)."

Preclinical • Non Small Cell Lung Cancer • Triple Negative Breast Cancer

New pipeline of nectin-targeting Nectin4-ADC ’LN-4305/LN-4311’ revealed. [Google translation] (HIT News) - "In this abstract presentation, LN-4305 and LN-4311 showed significant efficacy improvements compared to the previously approved Nectin4-ADC, Padcev (enfortumab vedotin), in multiple Nectin4-high-expressing cancer models, including triple-negative breast cancer (TNBC) and lung cancer. In a model of resistance to Padcep (ingredient: enfortumab vedotin), tumor suppression was observed with a single dose of LN-4305 and LN-4311."

Preclinical • Lung Cancer • Triple Negative Breast Cancer